David Dai
Stock Analyst at UBS
(0.85)
# 3,885
Out of 4,976 analysts
24
Total ratings
31.82%
Success rate
-18.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $37 → $35 | $17.04 | +105.40% | 2 | Jul 15, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $9.90 | +162.76% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $25.98 | +15.47% | 1 | Jul 1, 2025 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $17 → $2 | $2.49 | -19.68% | 2 | May 16, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $30 → $24 | $6.99 | +243.35% | 2 | May 12, 2025 | |
| NUVL Nuvalent | Upgrades: Buy | $100 | $80.89 | +23.62% | 2 | Mar 14, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $27 → $14 | $8.22 | +70.32% | 2 | Mar 6, 2025 | |
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $37.20 | -35.48% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $3.46 | +478.03% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $67.47 | +6.71% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $24.06 | +186.78% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $27.16 | +84.09% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $33.07 | +81.43% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.72 | +3,787.27% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $28.31 | +41.29% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $2.00 | +1,900.00% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.26 | +2,112.39% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $31.45 | +65.34% | 1 | Mar 17, 2020 |
Syndax Pharmaceuticals
Jul 15, 2025
Maintains: Buy
Price Target: $37 → $35
Current: $17.04
Upside: +105.40%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $9.90
Upside: +162.76%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $25.98
Upside: +15.47%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.49
Upside: -19.68%
Cullinan Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $6.99
Upside: +243.35%
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $80.89
Upside: +23.62%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27 → $14
Current: $8.22
Upside: +70.32%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $37.20
Upside: -35.48%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $3.46
Upside: +478.03%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $67.47
Upside: +6.71%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $24.06
Upside: +186.78%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $27.16
Upside: +84.09%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $33.07
Upside: +81.43%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.72
Upside: +3,787.27%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $28.31
Upside: +41.29%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $2.00
Upside: +1,900.00%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.26
Upside: +2,112.39%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $31.45
Upside: +65.34%